misterTP® schreef op 12 maart 2019 15:15:
[...]
Pagina 7 uit het jaarverslag:
Cash and cash equivalents
The cash position including restricted cash increased from €60.0 million at year-end 2017 to €81.5 million at year-end 2018. This was mainly due to the strong sales performance of RUCONEST® especially in the third and fourth quarters, and occurred despite considerable increases in marketing
8
and R&D activities and the repayment of over €14.5 million ($16.7 million) of the Orbimed loan facility.
Dus toename kasmiddelen van 21,5 miljoen plus 14,5 miljoen = 36 miljoen euro....